Telerx Expands Capabilities Through Acquisition of Sentrx Safety Solutions

September 06, 2013

Horsham, PA, April 8, 2013: Telerx, a leader in U.S. customer care services, has expanded its Pharmaceutical and Healthcare business unit by acquiring Sentrx Safety Solutions, a leading pharmacovigilance (drug safety) outsourcing service company.  The transaction positions the company for further expansion of one of its key vertical businesses. Telerx will retain Sentrx’s approximately 100 employees and executive leadership, and will gain the company’s outstanding client portfolio.

“The pharmaceutical and healthcare industries are undergoing unprecedented change and specialized services such as those provided by Telerx will grow in importance as entities within these industries work to meet new regulations,” said Linda Schellenger, President of Telerx. “We are confident that our acquisition of Sentrx will position us for faster growth and enable us to better serve the needs of our clients.”

According to Michael O’Gorman, CEO of Sentrx, “All of us at Sentrx are excited to be part of Telerx. By integrating our services and technologies with a company which has been successful in the healthcare space over the past 33 years, we will be able to more competitively offer the most comprehensive portfolio of services to a wide range of pharmaceutical companies and healthcare providers.”

“It will enable us to provide a full suite of drug safety solutions to the pharmaceutical and biotechnology marketplace,” added Linda Comp, Senior Vice President and General Manager of Telerx’s Pharmaceutical and Healthcare business unit. ”We look forward to working with our new employees and client partners gained through this acquisition.”

About Sentrx

Founded in 1995 and headquartered in Little Falls, NJ, Sentrx Safety Solutions provides pharmacovigilance (drug and device safety) services to the life sciences industry, safety data hosting services, additional regulatory services, special projects and other related technology services.

About Telerx

Telerx, a subsidiary of Merck & Co, Inc., offers complete management of complex and sensitive interactions in the healthcare marketplace including, access & reimbursement, product recalls and critical events, quality and compliance and patient assistance among others. The company adheres to strict regulatory requirements and standard operating procedures related to the Pharmaceutical industry. Over 90 percent of the company’s clients are FDA-regulated. Telerx has corporate headquarters in Horsham, Pennsylvania with additional contact centers in Allentown and Wilkes-Barre, Pennsylvania, El Paso, Texas and Kings Mountain, North Carolina. For more information visit Telerx.com and connect with us on Facebook and LinkedIn.

About Merck

Today’s Merck is a global healthcare leader working to help the world be well.  Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions.  We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. For more information, visit www.merck.com and connect with us on Twitter, Facebook and YouTube.

Merck Forward-Looking Statement

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Merck’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Merck’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.  Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Merck’s 2012 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

For Media Inquiries

Ela Voluck

For Telerx

610-455-2752

evoluck@vaultcommunications.com